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Abstract
Introduction Obesity is associated with many pathophysi-
ological changes that may result in altered drug metabo-
lism. The aim of this study is to investigate the influence of
obesity on the pharmacokinetics of morphine, morphine-3-
glucuronide (M3G), and morphine-6-glucuronide (M6G)
through a combined analysis in morbidly obese patients
and non-obese healthy volunteers.
Methods In this analysis, data from 20 morbidly obese
patients [mean body mass index 49.9 kg/m2 (range
37.6–78.6 kg/m2) and weight 151.3 kg (range
112–251.9 kg)] and 20 healthy volunteers [mean weight
70.6 kg (range 58–85 kg)] were included. Morbidly obese
patients received 10 mg of intravenous (I.V.) morphine
after gastric bypass surgery, with additional morphine I.V.
doses as needed. Healthy volunteers received an I.V. bolus
of morphine of 0.1 mg/kg followed by an infusion of
0.030 mg kg-1 h-1 for 1 h. Population pharmacokinetic
modeling was performed using NONMEM 7.2.
Results In morbidly obese patients, elimination clearance of
M3G and M6G was decreased substantially compared with
healthy volunteers (p\ 0.001). Regarding glucuronidation,
only a slight decrease in the formation ofM6G and a delay in
the formation of M3G was found (both p\ 0.001). Obesity
was also identified as a covariate for the peripheral volume of
distribution of morphine (p\ 0.001).
Conclusion Metabolism of morphine is not altered in mor-
bidly obese patients.However, decreased elimination of both
M3G and M6G is evident, resulting in a substantial increase
in exposure to these two metabolites. A rational explanation
of this finding is that it results from alterations in membrane
transporter function and/or expression in the liver.
ClinicalTrials.gov identifier: NCT01097148.
Key Points
Morphine concentrations proved similar between the
morbidly obese patients and non-obese patients,
indicating that no weight-based dosing adjustments
are necessary.
However, decreased elimination clearance of
morphine-3-glucuronide and morphine-6-
glucuronide in morbidly obese patients may result in
increased exposure to the metabolites.
It seems that the increased exposure to the two
metabolites may result from obesity-related
alterations in membrane transporter function and/or
expression in the liver.
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1 Introduction
The prevalence of obesity [bodymass index (BMI)[ 30 kg/
m2] and morbid obesity (BMI[ 40 kg/m2) is increasing,
with around 600 million obese people worldwide [1]. Obe-
sity is associated with an increase in morbidity and mortality
and numerous chronic diseases such as diabetes mellitus,
cardiovascular diseases, and cancer.
There are several (patho)physiological changes associ-
ated with morbid obesity that may impact the pharma-
cokinetics of drugs. Obesity has been associated with
changes in the expression and function of metabolic pro-
cesses such as cytochrome P450 and conjugation enzymes,
fatty liver infiltration, non-alcoholic steatohepatitis
(NASH), and altered transporters [2]. These changes have
been shown to impact the metabolism of certain drugs,
with for instance, increased glucuronidation of paracetamol
in morbidly obese patients [3], whereas the metabolism of
midazolam is unaltered in morbidly obese patients under-
going bariatric surgery compared with non-obese control
patients [4], but was found to increase after gastric bypass-
induced weight loss 1 year after surgery [5]. Data on liver
blood flow, glomerular filtration and/or tubular-mediated
mechanisms in morbidly obese patients are more incon-
clusive with, for example, data of unchanged cefazolin
clearance in morbidly obese patients and unchanged or
increased liver blood flow [2, 6].
Morphine is primarily metabolized by the liver uridine
diphosphate glucuronosyltransferase (UGT) 2B7 to phar-
macologically active metabolites morphine-3-glucuronide
(M3G) and morphine-6-glucuronide (M6G). M3G has
potential antagonistic or hyperalgesic properties [7], while
M6G appears to contribute to analgesia and sedation [8].
Despite the extensive use of morphine, data on the PK of
morphine and glucuronide metabolites in morbidly obese
patients are limited. A previous study reported an increased
ratio between morphine metabolites and morphine after
oral administration of morphine in gastric bypass patients
when comparing their results with data in the literature
[9–11]. In another study, intravenous morphine was
administered to 14 healthy volunteers and the results
compared with seven obese patients with biopsy-confirmed
NASH. This study also suggested a higher area under the
curve (AUC) of morphine glucuronides in NASH patients
compared with healthy volunteers [12].
In view of the higher susceptibility for pain and the
increased use of opioids in obese individuals [13], and the
fact that the adverse effects of opioids are feared in obese
populations because of the increased risk for respiratory
depression, respiratory failure, and other opioid adverse
effects [14, 15], knowledge on the pharmacokinetics of
morphine and its metabolites in morbidly obese patients is
necessary. This study investigates the pharmacokinetics of
morphine and its pharmacologically active glucuronides in
morbidly obese patients using a population approach on the
basis of a combined dataset of morbidly obese patients
together with a historic cohort of healthy volunteers
[16, 17].
2 Methods
2.1 Patients
The data obtained in the morbidly obese patients were
collected as part of a study in which the pharmacokinetics
of multiple drugs was investigated [18–20]. Anesthesia was
standardized with induction of anesthesia with propofol,
atracurium, and fentanyl, after which anesthesia was
maintained with continuous infusions of propofol and
remifentanil. For this original study, 20 morbidly obese
patients (BMI[ 40 kg/m2) were included who were
scheduled to undergo laparoscopic gastric banding, gastric
sleeve, or gastric bypass surgery (Table 1). Inclusion cri-
teria were age between 18 and 60 years, BMI[ 40 kg/m2,
American Society of Anesthesiologists (ASA) physical
status classification of II or III, and a normal renal and liver
function as assessed by routine laboratory testing. Exclu-
sion criteria were pregnancy, breastfeeding, and a known
allergy to morphine. This study was approved by the local
Human Research and Ethics Committee of St. Antonius
Ziekenhuis (VCMO, NL35861.100.11) and conducted in
accordance with the principles of the Declaration of Hel-
sinki and the Medical Research Involving Human Subjects
Act (WMO) of The Netherlands. Before participation, all
patients gave written informed consent.
For the control group, data were available from 20
healthy volunteers, 10 of each sex, who were enrolled as
part of two other studies of which detailed information can
be found in the references [16, 17]. The subjects were
healthy and did not have a history of illicit substance abuse.
Approval was obtained from the Human Ethics Committee
(Commissie Medisch Ethiek, Leids Universitair Medisch
Centrum, Leiden, The Netherlands: protocol No. P00.034).
Written and oral informed consent was given.
2.2 Study Design
In the prospective observational study (ClinicalTrials.gov:
NCT01097148), 20 morbidly patients were studied on the
day of gastric bypass surgery and afterwards. According to
standard care, all patients received a bolus injection of
10 mg of intravenous morphine at the end of the procedure
for the prevention and/or treatment of postoperative pain. If
needed based on the local postoperative pain protocol
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(Numerical Rating Scale C 4), patients received additional
intravenous boluses of morphine. Blood samples were
drawn before induction of anesthesia (t = 0) and after 5,
15, 30, 45, 75, 90, 120, 150, 250, and 420 min after the first
dose of intravenous morphine. Samples were immediately
stored on ice, and within 1 h, samples were centrifuged for
10 min at 4 C to obtain plasma samples and stored
immediately at -80 C until analysis.
The healthy volunteers received an intravenous bolus of
0.10 mg/kg of morphine followed by an infusion of
0.03 mg/kg/h for 1 h. Blood samples were collected at
fixed times (t = 5, 10, 20, 30, 40, 50, 60, 65, 70, 80, 100,
130, 180, 300, and 420 min) after the morphine bolus dose.
2.3 Analysis
Samples from both studies were analyzed in the same
laboratory using a solid-phase extraction and reverse-phase
high-performance liquid chromatography, which has been
published previously [16]. The lower limit of quantification
(LLOQ) for the obese population was 1 lg/L for morphine,
2 lg/L for M3G, and 1 lg/L for M6G. For the analytic
method of the healthy volunteer study, the LLOQ values
for morphine and M3G were 2 and 30 lg/L. For M6G, the
LLOQ values were 2, 5, and 6 lg/L.
2.4 Population Pharmacokinetic Analysis
and Internal Model Validation
Morphine and metabolite data of both datasets were ana-
lyzed using non-linear mixed-effects modeling with
NONMEM Version 7.2 software (Icon Development
Solutions, Hanover, MD, USA) [21]. Pirana Version 2.9.1
[22], R Version 3.0.1 [23], Xpose Version 4.5.0 [22], and
Psn Version 3.6.2 [22] software were used to evaluate and
visualize the data. Identifiability of the model was verified
using the COMBOS (UCLA Biocybernetics Laboratory
Los Angeles, CA, USA) software application (see Elec-
tronic Supplementary Material 1) [24].
Concentrations were expressed in nanomoles per liter,
using the molecular weights of morphine, M3G and M6G
(285.33 and 461.46 g/mol, respectively). The amount of
administrated morphine was corrected for morphine
hydrochloride (molecular weight 321.8 g/mol).
In the obese population, no data were below the LLOQ.
In the healthy volunteer study, 5% (n = 16 of 311) of the
morphine concentrations, 4.5% (n = 14 of 311) of the
M3G concentrations, and 9.6% (n = 30 of 311) of the
M6G concentrations were below the LLOQ. The first
below quantification observations were replaced with
LLOQ/2 and the rest were discarded, according to the M6
method for handling data below the limit of quantification
in population pharmacokinetic studies [25].
Discrimination between different models was made by
the likelihood ratio test using the objective function value
(OFV, i.e., -2 log likelihood [-2LL]). A p-value of\0.05,
representing a decrease of 3.84 in the OFV value between
nested models with one degree of freedom, was considered
statistically significant. In addition, goodness-of-fit plots
for morphine, M3G, and M6G [observed vs. individual-
predicted concentrations, observed vs. population-pre-
dicted concentrations, conditional weighted residuals
Table 1 Summary of patients characteristics
Morbidly obese patients (n = 20) Healthy volunteers (n = 20) P value
Male/female 9/11 10/10 0.752
Age (years) 44.1 ± 10.6 (22–59) 25.5 ± 4.1 (20–36) \0.001
Body weight (kg) 150.5 ± 33.3 (112.0–251.9) 70.6 ± 8.82 (56.0–85.0) \0.001
Body mass index (kg/m2) 49.9 ± 10.2 (37.9–78.6)
Type of surgery (n, %)
Gastric bypass 10 (50.0) N/A N/A
Gastric banding 7 (35.0)
Gastric sleeve 3 (15.0)
No. of samples per patient \0.001
Morphine, median (IQR) 10 (10–10) 15 (14–15)
M3G 10 (10–10) 15 (14–15)
M6G 10 (10–10) 15 (13–15)
Total amount of morphine (mg) 15.7 (4.0) 9.2 (1.2) \0.001
Serum creatinine, median (IQR) (lmol/L) 63 (60–81)a 80 (–) 0.014
Values are expressed as mean ± standard deviation (range) unless specified otherwise
IQR interquartile range, M3G morphine-3-glucuronide, M6G morphine-6-glucuronide, N/A not applicable
a One value missing
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(CWRES) vs. time, and CWRES vs. population-predicted
concentrations plots] were used for diagnostic purposes.
Residual variability was tested using proportional, additive,
or combined proportional and additive error models. Fur-
thermore, the confidence interval of the parameter esti-
mates, the correlation matrix, and visual improvement of
the individual plots were used to evaluate the model. The
delay in formation of morphine metabolites was captured
by testing a varying number of transit compartments. Mean
transit time (MTT) was calculated from the transit com-
partment rate constant (Ktr) with n/Ktr, where n is the
number of transit compartments.
The non-glucuronide clearance (direct unchanged uri-
nary clearance and non-glucuronide metabolic clearance)
was assumed to be 35% of total clearance of a 70-kg
healthy subject, based on previous reports [26]. Total
clearance (CLtotal) was calculated as M3G clearance
(CLM3G) ? M6G clearance (CLM6G) ? non-glucuronide
clearance (CLnonglucuronide). The volume of distribution of
the two metabolites M3G and M6G was assumed to be
equal (VM3G = VM6G), owing to their comparable
molecular structure and weight. Bootstrap procedure
using 200 replicates was used to obtain non-parametric
confidence intervals and to assess model robustness [27].
Predictability was evaluated with the normalized predic-
tion distribution error method (2000 samples). Results of
the normalized prediction distribution error are incorpo-
rated in the goodness-of-fit plots, as a replacement of
CWRES vs. time and CWRES vs. population-predicted
concentrations.
2.5 Covariate Analysis
Covariates were plotted independently against the indi-
vidual estimates of pharmacokinetic parameters to visual-
ize potential relations. Total body weight (TBW) was the
main covariate of interest in this study. Age and sex were
tested in preliminary models but were further explored in
the final model. BMI was not tested because no individual
height was available of the healthy volunteers. Continuous
covariates were tested using both power and linear
equations:
Pi ¼ Pp  ð1þ Y  ðCOV  COVmedianÞÞ; ð1Þ
Pi ¼ Pp  ðCOV  COVmedianÞX ; ð2Þ
where Pi and Pp represent individual and population
parameter estimates, COV represents the covariate,
COVmedian represents the median of the value of the
covariate for the population, Y represents a correlation
factor between the population parameter and the change in
covariate value for a linear function, and X represents the
exponential scaling factor for a power function. The
categorical covariate (sex) was examined by calculating a
separate parameter for each category of the covariate.
Potential covariates were separately entered into the
model and statistically tested by use of the likelihood ratio
test. In addition, if applicable, it was evaluated whether the
inter-individual variability (eta) in the parameter concerned
decreased upon inclusion of the covariate on the parameter
and whether the plot of the eta vs. covariate was improved.
Finally, using forward inclusion (p\ 0.05, OFV decrease
[3.8) and backward deletion (p\ 0.001, OFV decrease
10.8), it was justified to include the covariate.
2.6 Simulations
The final population pharmacokinetic model was used to
simulate concentration–time curves. An intravenous bolus
of 10 mg of morphine HCL was simulated in four patients;
two extremes of dataset (respectively, 56 and 251.9 kg)
and two patients in-between. Morphine as well as M3G and
M6G concentrations were plotted vs. time.
2.7 Statistical Analysis
Continuous data are presented as median (interquartile
range (IQR)) and analyzed using the Mann–Whitney test,
or as mean ± standard deviation and analyzed using the
Student’s t test, where appropriate.
3 Results
3.1 Patients
Twenty morbidly obese patients and 20 healthy volunteers
were available for analysis. In total, in the obese group, 196
morphine, 196 M3G, and 196 M6G plasma samples were
included for analysis. In the healthy volunteers, a total of
290 plasma samples of morphine, 289 plasma samples of
M3G, and 285 plasma samples of M6G were included.
Differences were the result of the samples below the
LLOQ. A summary of patient characteristics is presented in
Table 1. Morbidly obese patients received a higher mor-
phine dose compared with the healthy volunteers
(15.7 ± 4.0 mg vs. 9.2 ± 1.2 mg, p\ 0.05).
3.2 Population Pharmacokinetic Model
and Internal Model Evaluation
A three-compartment model for morphine, and a one-
compartment model for M3G and M6G, with equalized
volumes of distribution best fitted the data (Fig. 1). The
introduction of multiple transit compartments in the for-
mation of the glucuronides (for M3G n = 5, mean transit
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time = 3.05 min; for M6G n = 2, mean transit
time = 12.7 min) improved the model significantly
(p\ 0.001). Residual variability was best described by
proportional error models, one for each compound, and
calculated separately for each group. Table 2 shows the
parameter estimates of the simple model without
covariates.
In the covariate analysis, no substantial influence of
TBW on the clearance of morphine was found. Significant
influence of TBW was found on several other parameters,
all in a non-linear manner. Elimination clearance of both
metabolites decreased with TBW (CLE M3G p\ 0.001, -
16 OFV, CLE M6G p\ 0.001, -92 OFV), and the periph-
eral volume of morphine increased significantly with
increasing TBW (p\ 0.001, -34 OFV). Formation clear-
ance of M6G decreased with increasing TBW (CLF M6G
p\ 0.001, -26 OFV). Formation of M3G was delayed
with increasing body weight because the mean transit time
was increased with TBW [Ktr (p\ 0.001, -28 OFV)].
Imputing these functions resulted in a reduction in inter-
individual variability (CLF M3G 24.3–20.8%, CLE M3G
89.0–65.9%, VM3G = VM6G 32.3–29.7%, and Ktr2
37.7–36.8%) (see Table 2). Goodness-of-fit plots of the
final covariate model are shown in Fig. 2. The empirical
Bayes estimates (EBEs) after adding the covariate func-
tions are shown in Fig. 3. This figure shows the population-
predicted outcomes of the final covariate model and the
influence of TBW on the parameters, where adding TBW
improved the model significantly. Final model parameters
are summarized in Table 2. The bootstrap analysis was
successful in 98.5% of the runs and the obtained parameter
confidence intervals were highly similar to the confidence
intervals obtained from the standard errors (Table 2).
3.3 Simulations
Figure 4 shows the model-predicted concentration–time
profiles of morphine and its metabolites after an intra-
venous bolus dose of 10 mg of morphine and a 48-h con-
tinuous infusion of 2 mg h-1 in four representative
individuals from this study with a TBW of 56, 75, 125, and
253 kg. The figure shows that the pharmacokinetic profile
of morphine (panels A, D) in this weight range is compa-
rable. However, more pronounced differences are shown in
the morphine glucuronides. Here, when a bolus of mor-
phine is given, the maximum concentration of M3G is
higher in obese patients (panel B). In addition, as a result of
decreased elimination clearance, the AUC is also increased
in these patients. For M6G (panel C), an effect of TBW on
formation clearance and elimination clearance results in
lower peak concentrations, but an increased AUC in obese
patients. After a continuous infusion of 48 h of infusion,
the 253-kg patient has approximately a five times higher
concentration of M3G and a three times higher concen-
tration of M6G compared with the 56-kg healthy volunteer
(panels D, E).
4 Discussion
As limited data are available on the pharmacokinetics of
morphine in morbidly obese patients, this study aimed to
evaluate the influence of obesity on the metabolism of
intravenously administered morphine and its pharmaco-
logically active glucuronides (M3G and M6G). The results
of this study show that, besides a slight decrease in the
formation of M6G, the formation clearance of the main
metabolite M3G is similar between the groups, although
the formation was delayed. It has been reported before, that
UGT-mediated drug metabolism is potentially increased in
obese patients in comparison with non-obese patients [28];
for example, paracetamol glucuronidation (and sulfation) is
increased in obese patients [3]. The lack of influence of
obesity on morphine glucuronidation in the present study
may be explained by the fact that morphine is a medium-
Fig. 1 Schematic of the population pharmacokinetic model of
morphine and morphine glucuronides. CLF formation clearance,
CLE elimination clearance, Ktr transit rate constant, M3G morphine-
3-glucuronide, M6G morphine-6-glucuronide, Q inter-compartmental
clearance from the central compartment of morphine to the peripheral
compartments of morphine, V1 central volume of distribution,
V4M,V5M peripheral compartments of morphine, V3M6G = V2M3G
central volumes of morpine glucuronides, CLnon-glucuronide = 35% of
Cltotal (70 kg), CLtotal = Clnon-glucuronide ? CLF M3G ? CLF M6G
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Table 2 Population pharmacokinetic parameters of the base and final pharmacokinetic model for morphine and glucuronides in healthy
volunteers and morbidly obese patients and results of the bootstrap analysis
Parameter Base model (RSE%) Final model (RSE%) Bootstrap (95% confidence interval)
Morphinea
CLF M3G (L/min) 0.725 (4.0) 0.748 (3.0) 0.748 (0.706–0.797)
CLF M6G (L/min) 0.128 (6.0)
CLF M6G = CLF M6G, 98.5 kg  (TBW/98.5)K
CLF M6G, 98.5 kg (L/min) 0.129 (5.0) 0.130 (0.119–0.140)
K -0.329 (36.0) -0.310 (-0.534 to -0.125)
V1M (L) 3.96 (5.0) 4.62 (9.0) 4.66 (3.95–5.59)
V4M (L) 5.76 (18.0) 9.52 (33.0) 9.91 (6.10–15.7)
V5M (L) 101 (5.0)
V5M = V98.5 kg  (TBW/98.5)L
V98.5 kg (L) 118 (9.0) 117.5 (103.7–136.6)
L 0.483 (48.0) 0.453 (0.112–0.859)
Q2 (L/min) 0.625 (7.0) 0.814 (20.0) 0.834 (0.598–1.16)
Q3 (L/min) 1.27 (5.0) 1.29 (5.0) 1.28 (1.15–1.41)
Ktr (min-1) 1.58 (9.0)
Ktr = Ktr98.5 kg  (TBW/98.5)M
Ktr98.5 kg (min
-1) 1.68 (9.0) 1.71 (1.51–1.98)
M -0.701 (30.0) -0.71 (-0.106 to 0.375)
Ktr2 (min-1) 0.151 (5.0) 0.159 (7.0) 0.158 (0.146–0.172)
Metabolites (M3G, M6G)
VM3G = VM6G (L) 6.47 (7.0) 5.29 (13.0) 5.33 (4.28–6.52)
CLE M3G (L/min) 0.131 (14.0)
CLE M3G = CLE M3G, 98.5 kg  (TBW/98.5)N
CLE M3G, 98.5 kg (L/min) 0.134 (10.0) 0.134 (0.110–0.155)
N –1.08 (22.0) –1.06 (–1.53 to -0.60)
CLE M6G (L/min) 0.171 (15.0)
CLE M6G = CLE M6G, 98.5 kg  (TBW/98.5)O
CLE M6G, 98.5 kg (L/min) 0.149 (10.0) 0.154 (0.125–0.186)
O –1.03 (31.0) –1.06 (–1.64 to –0.56)
Inter-individual variability (%)
CLF M3G 24.3 (12.0) 20.8 (10.0) 20.3 (16.8–23.4)
CLE M3G 89.0 (19.0) 65.9 (20.0) 62.9 (41.9–86.1)
VM3G = VM6G 32.3 (12.0) 29.7 (12.0) 29.2 (22.6–35.8)
Ktr2 37.7 (13.0) 36.8 (13.0) 35.9 (27.1–43.6)
Residual variability (%)
Healthy volunteers
Proportional error for morphine 15.1 (16.0) 14.0 (7.0) 13.8 (12.0–15.7)
Proportional error for M3G 18.0 (25.0) 17.9 (12.0) 18.0 (14.3–21.5)
Proportional error for M6G 30.4 (19.0) 29.5 (8.0) 29.3 (24.2–32.8)
Morbidly obese patients
Proportional error for morphine 37.3 (22.0) 37.9 (11.0) 37.1 (29.2–44.7)
Proportional error for M3G 18.4 (17.0) 17.1 (8.0) 17.1 (14.9–19.1)
Proportional error for M6G 32.8 (37.0) 28.1 (9.0) 26.5 (21.5–30.7)
OFV (-2LL) 10,311.38 10,116.1 10,038.1 (9774.8–10,306.3)
CLF formation clearance, CLE elimination clearance, Ktr transit rate constant, LL log likelihood, M3G morphine-3-glucuronide, M6G morphine-
6-glucuronide, OFV objective function variable, Q inter-compartmental clearance from the central compartment of morphine to the peripheral
compartments of morphine, RSE relative standard error, TBW total body weight, V volume of distribution (see also Fig. 1)
a Formation clearances are reported as absolute values, with CLF M3G and CLF M6G being 65% of total morphine clearance (see also Fig. 1)
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to-high extraction ratio drug, assuming liver blood flow
remains unchanged in morbidly obese patients [2]. Such
drugs are rapidly metabolized depending on hepatic blood
flow and are relatively insensitive to changes in enzyme
activity [14].
The most important finding of the current study is the
decrease in elimination clearance of both morphine glu-
curonides, and the resulting increased exposure to these
metabolites that may therefore be expected in the obese
patients (Fig. 4). Increased AUC ratios of glucuronides:-
morphine in obese patients when compared with the meta-
bolic ratios reported for healthy adults in the literature have
been reported before [10]. However, from a physiological
perspective, these results are somewhat unexpected because
the elimination of morphine glucuronides in animals is
mainly through renal excretion; i.e., only about 20% of the
morphine glucuronides is excreted through bile [29–31].
Therefore, we did not expect such a dramatic reduction in
glucuronide clearance in the obese patients, as the routine
blood tests of renal function around surgery show no indi-
cation that our obese patients had an impaired renal func-
tion. A more likely explanation is that the elimination of the
morphine glucuronides in the bile plays a much larger role in
special patient populations than previously thought, imply-
ing a significant role for hepatic transporters.
Multidrug resistance proteins MRP2 (ABCC2) and
MRP3 (ABCC3) are known to be involved in the transport
of morphine and metabolites. MRP2 is mainly involved in
the efflux of molecules from hepatocytes to the bile, while
MRP3 is involved in the efflux from hepatocytes to plasma
[32]. A decrease in MRP2 activity could therefore lead to a
decrease in morphine glucuronide elimination. It is also
likely that obese individuals could have decreased MRP2
activity as a result of NASH. This condition is associated
with alterations in the expression and function of metabo-
lizing enzymes and transporters [33, 34]. In a NASH model
in the rat, impaired function of MRP2 resulted in signifi-
cantly reduced biliary excretion of M3G [32]. Furthermore,
there is genetic evidence in humans that the activity of
MRP2 is critical for biliary excretion of substrates. In an
inherited medical condition known as Dubin–Johnson
syndrome, dysfunctional mutations in the MRP2 gene
cause impairment in biliary excretion of bilirubin, such as
bilirubin glucuronides. Together with upregulation of
MRP3, this results in jaundice in patients with Dubin–
Johnson syndrome [35].
Fig. 2 Goodness-of-fit plots of morbidly obese individuals (n = 20,
blue squares) and healthy volunteers (n = 20, red rounds). On the
first row morphine (a), second row morphine-3-glucuronide (b), and
third row morphine-6-glucuronide (c). Please note the scale differ-
ences in the y-axis. conc. concentration, NPDE normalized prediction
distribution error
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A recent clinical study measured bile acids as a surro-
gate parameter for the activity of protein expression of the
hepatic basolateral efflux transporter Mrp-3 [12]. Seven
obese patients (mean BMI of 32 kg m-2) with confirmed
NASH were included in a non-compartmental analysis and
no differences in the pharmacokinetics of morphine com-
pared with healthy subjects were found. Healthy volunteers
had no liver biopsy to confirm the absence of NASH.
However, an increase of around 50% in the AUC of the
glucuronides in the patients with NASH was reported [12].
Upregulated MRP3 could increase the efflux from the
hepatocytes to plasma, thereby reducing the concentrations
available to be excreted to bile by MRP2 and thus
increasing the residence time of M3G in plasma. The
question is whether a combination of upregulated MRP3
and a decreased functional MRP2 can account completely
for the increased exposure to morphine glucuronides in
obese patients. This study of Ferslew et al. shows that
increasing severity of NASH correlates with increasing bile
acids, meaning that increasing NASH severity may further
increase MRP3-mediated efflux clearance [12]. Taking into
consideration that our patients have a far greater BMI index
(mean 49.9 kg m-2) compared with this study, the impact
of the MRP2/MRP3 transporters is potentially even greater.
Remarkably, accumulation of the morphine glu-
curonides is also seen in other patient populations. The
Fig. 3 Post-hoc parameters estimates of morbidly obese individuals
(n = 20, blue squares) and healthy volunteers (n = 20, red rounds)
from the final model vs. total body weight, including morphine-3-
glucuronide elimination clearance (CLE M3G) vs. total body weight
(a), morphine-6-glucuronide elimination clearance (CLE M6G) vs.
total body weight (b), morphine-3-glucuronide transit rate constant
(Ktr) vs. total body weight (c), morphine-6-glucuronide transit rate
constant (Ktr2) vs. total body weight (d), peripheral volume of
distribution of morphine (V1M) vs. total body weight (e), and
formation clearance of morphine-6-glucuronide (CLF M6G) vs. total
body weight (f)
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study of Ahlers et al. compared patients in an intensive care
unit (ICU) (i.e., cardiac surgery patients and critically ill
patients) with healthy volunteers and found that M3G
elimination clearance was decreased independently of the
creatinine levels [36]. Because these patients had a BMI of
around 28 kg m-2, it is possible that obesity-related factors
may have caused these results. Moreover, another study
found increased expression of MRP3 protein in post-mor-
tem biopsy samples of critically ill patients in an ICU [37].
Similar results on the accumulation of morphine glu-
curonides have been reported in children undergoing car-
diac surgery compared with children not undergoing
cardiac surgery [38]. Whether induction or inactivation of
transporters in the acute setting such as surgery can play a
role in the metabolism of drugs is an area for future
research. For example, a rat model of acute sepsis showed
upregulation of MRP3 mRNA levels [39].
The time–concentration simulations in Fig. 4 illustrate
the large increase in exposure to M3G and M6G that may
be expected in individuals of varying body weights.
Although the structure of the metabolites is quite similar,
the effect of TBW on their profiles is different. This is the
result of the different covariate functions on the M6G
compared with M3G, and possibly of the lower fraction of
morphine that is converted to M6G and the different UGT
enzymes responsible for glucuronidation of the metabolites
[8]. The clinical relevance of increased concentrations of
M3G and M6G is however not clear. The general
assumption is that M3G, although showing higher plasma
concentrations, has lower opioid receptor binding affinity
compared with morphine and lacks opioid activity,
although some studies have reported anti-analgesic effects
[40–42]. However, M6G binds with high affinity to the
opioid receptor and contributes to the analgesic properties
of morphine [8]. There is a slow equilibration of the glu-
curonides between plasma and effect sites in the central
nervous system, which is why the contribution of the glu-
curonides can become more important in prolonged expo-
sure or decreased clearance for example in renal failure
[43]. Recently, it has become clear that morbidly obese
patients 6 months after gastric bypass surgery had an
increase in morphine exposure after oral administration [9].
The exposure of morphine increased probably because of
an increase in absorption, while the exposure of glu-
curonides remained the same compared to the pre-surgery
state. This suggests a pathophysiological change after
weight loss such as a decrease in glucuronidation capacity,
an increase in elimination clearance, or altered liver blood
flow and/or liver membrane transporters. There were some
limitations in this study. First, even though the impact is
expected to be small because morphine is administered at
the end of surgery, the effects of anesthesia and surgery on
the pharmacokinetics of morphine and its metabolites
cannot be assessed. Second, morbidly obese patients were
not screened for the presence of NASH because no liver
biopsy was taken. Third, TBW was the only body size
Fig. 4 Population predicted morphine, morphine-3-glucuronide
(M3G), and morphine-6-glucuronide (M6G) concentrations over time
in four typical study patients (56, 75, 125, and 253 kg) after a 10-mg
intravenous bolus dose of morphine hydrochloride (a–c) and a 2-mg/h
continuous infusion of morphine hydrochloride for 48 h (d–f)
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descriptor available to investigate in this study. Last, no
urinary samples were available to measure the concentra-
tions of morphine and its metabolites. In this study, the
measurements of morphine, M3G and M6G concentrations
came from the same blood samples. The measurements can
therefore be assumed to be correlated. While it would have
been technically possible to estimate the intra-sample
correlations between the concentrations, this was not con-
sidered relevant for the estimation of the pharmacokinetic
parameters, their variances, and their covariates.
Future studies evaluating the influence of hepatic
transporters and bile acid homeostasis in morbidly obese
patients and after bariatric surgery are needed to under-
stand more of the pathophysiological changes associated
with obesity. In addition, studies should evaluate the clin-
ical effects of increased morphine glucuronides in terms of
efficacy and safety.
5 Conclusion
In morbidly obese patients, the pharmacokinetics of mor-
phine are comparable to healthy volunteers, thus no
weight-based dosing adjustments are necessary for phar-
macokinetic purposes. However, the elimination clearances
of both M3G and M6G are significantly decreased,
resulting in increased exposure to the metabolites, espe-
cially with prolonged administration of morphine. A sug-
gested underlying mechanism is a change in membrane
transporters that are associated with patients with NASH, a
hepatic condition common in obese individuals. Additional
mechanisms of increased glucuronide concentrations is an
area for future research, together with the pharmacody-
namic and clinical consequences of increased M3G and
M6G concentrations, especially.
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